Novo Nordisk (CPSE:NOVO B) just reported third quarter 2026 earnings, giving investors fresh numbers on sales, profit and earnings per share after a mixed year for the stock. Recent trading has been choppy for Novo Nordisk, with the share price climbing 4.1% over the past week and 8.6% over the past month, but still sitting well below earlier levels after an 18.2% decline in the year to date and a 10.2% drop in 1 year total shareholder return. Stronger third quarter earnings, a higher full year outlook, fresh obesity data heading into ObesityWeek 2026, the once weekly Awiqli approval and an ongoing DKK 15b buyback have helped rebuild some short term momentum after a tougher multi year stretch, highlighted by a 58.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.